We have already shown that cytokeratin 4 (CK4) protein expression is a favorable prognostic factor for the patients with locally advanced TSCC. The aim of this study is to identify predictive markers of TSCC recurrence and cancer specific death among clinicopathological factors including CK4 protein expression.
Two cohorts including discovery (79 cases) and validation (94 cases) cohorts consisting of the patients with primary TSCC were evaluated. Eligibility criteria were as follows: 1) preoperative imaging diagnosis of cT1/2N0; 2) primary partial glossectomy without lymph node dissection; and 3) TSCCs with pT1/2. The relationship between clinicopathological factors and relapse-free survival (RFS) and cancer specific survival (CSS) was statistically analyzed.
Median age, pT, median tumor thickness and rate of positive immunohisthochemical staining for CK4 in tumor cells in discovery cohort were 63 years (26-89), pT1/2 = 47%/53%, 6 mm (0.75-16), and 59%, respectively. 3-year RFS and 3-year CSS rates were 70.3% and 94.5%, respectively. Multivariate analysis indicated that pT [pT2 vs. pT1, hazard ratio (HR) of 2.63], tumor thickness [≥5mm vs.
CK4 is a novel predictive marker for recurrence in early TSCC. The combination of CK4 with clinicopathlogical factors predicted recurrence and cancer specific death in this population.
Clinical trial identification
Legal entity responsible for the study
National cancer center
All authors have declared no conflicts of interest.